LogicBio Therapeutics, Inc. (OTCMKTS:LOGC – Get Free Report) shares saw strong trading volume on Monday. Approximately 643,184 shares changed hands during mid-day trading, an increase of 383% from the average daily volume of 133,170 shares. The stock last traded at $15.00 and had previously closed at $15.15.
LogicBio Therapeutics Trading Down 6.3%
The firm’s fifty day simple moving average is $14.76 and its 200-day simple moving average is $10.34. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.24 and a current ratio of 1.87. The stock has a market cap of $649.38 million, a P/E ratio of -19.45 and a beta of 2.11.
LogicBio Therapeutics (OTCMKTS:LOGC – Get Free Report) last released its quarterly earnings data on Monday, November 9th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.25).
LogicBio Therapeutics Company Profile
LogicBio Therapeutics, Inc was a clinical-stage genetic medicine company focused on developing therapies for patients with serious genetic and metabolic diseases. The company’s research centered on genetic medicine technologies designed to address the underlying causes of disease rather than treat symptoms alone.
LogicBio’s principal platform, GeneRide, was developed to enable the targeted insertion of therapeutic genes into the genome. The company also pursued GeneWare, a platform intended to support gene-editing applications.
Further Reading
- Five stocks we like better than LogicBio Therapeutics
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
- Want to Escape the AI Sell-Off? This ETF Offers a Surprising Alternative
Receive News & Ratings for LogicBio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LogicBio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
